Bionano Genomics Return On Asset vs. Current Valuation
| BNGO Stock | USD 0.24 0.02 7.69% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.34 | 0.2649 |
|
|
For Bionano Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bionano Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bionano Genomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bionano Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bionano Genomics over time as well as its relative position and ranking within its peers.
Bionano |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bionano Genomics Current Valuation vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bionano Genomics's current stock value. Our valuation model uses many indicators to compare Bionano Genomics value to that of its competitors to determine the firm's financial worth. Bionano Genomics is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionano Genomics' earnings, one of the primary drivers of an investment's value.Bionano Current Valuation vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Bionano Genomics |
| = | -0.33 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bionano Genomics |
| = | 25.86 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Bionano Current Valuation vs Competition
Bionano Genomics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 15.62 Billion. Bionano Genomics adds roughly 25.86 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Bionano Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bionano Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bionano Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Bionano Genomics' change in net profit over the period of time. It can combine multiple indicators of Bionano Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 23 K | 24.1 K | |
| Net Interest Income | -1.8 M | -1.9 M | |
| Interest Income | 3.3 M | 3.5 M | |
| Operating Income | -215.2 M | -204.5 M | |
| Net Loss | -232.5 M | -220.9 M | |
| Income Before Tax | -232.4 M | -220.8 M | |
| Total Other Income Expense Net | -17.2 M | -16.3 M | |
| Net Loss | -119.3 M | -113.4 M | |
| Net Loss | -232.5 M | -220.9 M | |
| Income Tax Expense | 62 K | 65.1 K | |
| Non Operating Income Net Other | -200.7 K | -190.7 K | |
| Change To Netincome | 29 M | 30.4 M | |
| Net Loss | (6.81) | (7.15) | |
| Income Quality | 0.54 | 1.05 | |
| Net Income Per E B T | 1.00 | 1.09 |
Bionano Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bionano Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bionano Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bionano Genomics' important profitability drivers and their relationship over time.
Use Bionano Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Bionano Genomics Pair Trading
Bionano Genomics Pair Trading Analysis
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bionano Genomics position
In addition to having Bionano Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Funds Thematic Idea Now
Money Funds
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
To fully project Bionano Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bionano Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bionano Genomics' income statement, its balance sheet, and the statement of cash flows.